These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 26995298)

  • 1. Effect of antidepressant treatment on cognitive impairments associated with depression: a randomised longitudinal study.
    Shilyansky C; Williams LM; Gyurak A; Harris A; Usherwood T; Etkin A
    Lancet Psychiatry; 2016 May; 3(5):425-35. PubMed ID: 26995298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of a Machine Learning Model Based on Pretreatment Symptoms and Electroencephalographic Features to Predict Outcomes of Antidepressant Treatment in Adults With Depression: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Rajpurkar P; Yang J; Dass N; Vale V; Keller AS; Irvin J; Taylor Z; Basu S; Ng A; Williams LM
    JAMA Netw Open; 2020 Jun; 3(6):e206653. PubMed ID: 32568399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frontoparietal Activation During Response Inhibition Predicts Remission to Antidepressants in Patients With Major Depression.
    Gyurak A; Patenaude B; Korgaonkar MS; Grieve SM; Williams LM; Etkin A
    Biol Psychiatry; 2016 Feb; 79(4):274-81. PubMed ID: 25891220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cognitive-emotional biomarker for predicting remission with antidepressant medications: a report from the iSPOT-D trial.
    Etkin A; Patenaude B; Song YJ; Usherwood T; Rekshan W; Schatzberg AF; Rush AJ; Williams LM
    Neuropsychopharmacology; 2015 May; 40(6):1332-42. PubMed ID: 25547711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol.
    Williams LM; Rush AJ; Koslow SH; Wisniewski SR; Cooper NJ; Nemeroff CB; Schatzberg AF; Gordon E
    Trials; 2011 Jan; 12():4. PubMed ID: 21208417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antidepressant Outcomes Predicted by Genetic Variation in Corticotropin-Releasing Hormone Binding Protein.
    O'Connell CP; Goldstein-Piekarski AN; Nemeroff CB; Schatzberg AF; Debattista C; Carrillo-Roa T; Binder EB; Dunlop BW; Craighead WE; Mayberg HS; Williams LM
    Am J Psychiatry; 2018 Mar; 175(3):251-261. PubMed ID: 29241359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Cognitive Biotype of Depression and Symptoms, Behavior Measures, Neural Circuits, and Differential Treatment Outcomes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Hack LM; Tozzi L; Zenteno S; Olmsted AM; Hilton R; Jubeir J; Korgaonkar MS; Schatzberg AF; Yesavage JA; O'Hara R; Williams LM
    JAMA Netw Open; 2023 Jun; 6(6):e2318411. PubMed ID: 37318808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amygdala Reactivity to Emotional Faces in the Prediction of General and Medication-Specific Responses to Antidepressant Treatment in the Randomized iSPOT-D Trial.
    Williams LM; Korgaonkar MS; Song YC; Paton R; Eagles S; Goldstein-Piekarski A; Grieve SM; Harris AW; Usherwood T; Etkin A
    Neuropsychopharmacology; 2015 Sep; 40(10):2398-408. PubMed ID: 25824424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of antidepressant medication on emotion regulation in depressed patients: an iSPOT-D report.
    McRae K; Rekshan W; Williams LM; Cooper N; Gross JJ
    J Affect Disord; 2014 Apr; 159():127-32. PubMed ID: 24679400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain imaging predictors and the international study to predict optimized treatment for depression: study protocol for a randomized controlled trial.
    Grieve SM; Korgaonkar MS; Etkin A; Harris A; Koslow SH; Wisniewski S; Schatzberg AF; Nemeroff CB; Gordon E; Williams LM
    Trials; 2013 Jul; 14():224. PubMed ID: 23866851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heart rate variability as a biomarker of anxious depression response to antidepressant medication.
    Kircanski K; Williams LM; Gotlib IH
    Depress Anxiety; 2019 Jan; 36(1):63-71. PubMed ID: 30311742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABCB1 Genetic Effects on Antidepressant Outcomes: A Report From the iSPOT-D Trial.
    Schatzberg AF; DeBattista C; Lazzeroni LC; Etkin A; Murphy GM; Williams LM
    Am J Psychiatry; 2015 Aug; 172(8):751-9. PubMed ID: 25815420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of nonremission to antidepressant therapy using diffusion tensor imaging.
    Grieve SM; Korgaonkar MS; Gordon E; Williams LM; Rush AJ
    J Clin Psychiatry; 2016 Apr; 77(4):e436-43. PubMed ID: 27137427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial.
    Arnow BA; Blasey C; Williams LM; Palmer DM; Rekshan W; Schatzberg AF; Etkin A; Kulkarni J; Luther JF; Rush AJ
    Am J Psychiatry; 2015 Aug; 172(8):743-50. PubMed ID: 25815419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomised controlled trial assessing the severity and duration of depressive symptoms associated with a clinically significant response to sertraline versus placebo, in people presenting to primary care with depression (PANDA trial): study protocol for a randomised controlled trial.
    Salaminios G; Duffy L; Ades A; Araya R; Button KS; Churchill R; Croudace T; Derrick C; Dixon P; Dowrick C; Gilbody S; Hollingworth W; Jones V; Kendrick T; Kessler D; Kounali D; Lanham P; Malpass A; Peters TJ; Riozzie D; Robinson J; Sharp D; Thomas L; Welton NJ; Wiles N; Lewis G
    Trials; 2017 Oct; 18(1):496. PubMed ID: 29065916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Normalization of EEG in depression after antidepressant treatment with sertraline? A preliminary report.
    van der Vinne N; Vollebregt MA; Boutros NN; Fallahpour K; van Putten MJAM; Arns M
    J Affect Disord; 2019 Dec; 259():67-72. PubMed ID: 31437703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The international Study to Predict Optimized Treatment in Depression (iSPOT-D): outcomes from the acute phase of antidepressant treatment.
    Saveanu R; Etkin A; Duchemin AM; Goldstein-Piekarski A; Gyurak A; Debattista C; Schatzberg AF; Sood S; Day CV; Palmer DM; Rekshan WR; Gordon E; Rush AJ; Williams LM
    J Psychiatr Res; 2015 Feb; 61():1-12. PubMed ID: 25586212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).
    Fedgchin M; Trivedi M; Daly EJ; Melkote R; Lane R; Lim P; Vitagliano D; Blier P; Fava M; Liebowitz M; Ravindran A; Gaillard R; Ameele HVD; Preskorn S; Manji H; Hough D; Drevets WC; Singh JB
    Int J Neuropsychopharmacol; 2019 Oct; 22(10):616-630. PubMed ID: 31290965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of event-related potentials in predicting antidepressant treatment response: An iSPOT-D report.
    van Dinteren R; Arns M; Kenemans L; Jongsma ML; Kessels RP; Fitzgerald P; Fallahpour K; Debattista C; Gordon E; Williams LM
    Eur Neuropsychopharmacol; 2015 Nov; 25(11):1981-90. PubMed ID: 26282359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.